Skip to main content
. 2017 Nov 20;8:1594. doi: 10.3389/fimmu.2017.01594

Table 1.

Inducers of immunogenic cell death (ICD) in melanoma.

Model system ICD biomarker(s) Bona fide ICDa Reference
Chemotherapies
Doxorubicin B16-F10 Not determined Yes (67)
Oxilaplatin B16-F10 Calreticulin, ATP, high-mobility group box 1 (HMGB1) Yes (68, 69)
Melphalan A375 IL-8, CCL2, heat shock protein 90 (HSP90) Not tested (70)
B78 HSP90 Yes
Lidamycin B16-F1 Calreticulin Yes (207)
R2016 heterocyclic quinone B16-F10 Calreticulin, HMGB1, HSP60, HSP70, HSP90 Not tested (208)
Ginsenoside Rg3 B16-F10 Calreticulin, HSP60, HSP70, HSP90 Not tested (209)

Antimicrobial/oncolytic peptides
LTX-315 B16-F1 HMGB1 Not tested (76)
LTX-401 B16-F1 HMGB1, ATP, cytochrome c Not tested (77)

Oncolytic viruses
Measles virus Primary melanoma cells IL-6, IL-8 Not tested (78)
Mel888, Mel624, MeWO, SkMel28 IL-6, IL-8, type I IFN, HMGB1
Vaccinia virus SK29-MEL HMGB1, calreticulin (strain-dependent) Not tested (79)
Reovirus (type 3 Dearing strain) Mel888, Mel624, MeWO, SkMel28 Proinflammatory cytokines (cell line-dependent) Not tested (80)

Targeted therapies
Vemurafenib A375, 451-LU, M1617 Calreticulin, HSP90 Not tested (82)
U0126 (MEK inhibitor) A375, 451-LU, M1617 Calreticulin, HSP90 Not tested (82)
Bortezomib A375, 451-LU, M1617 Calreticulin, HSP90 Not tested (82)

Physical modalities
Hyperthermia ± ionizing radiation B16-F10 HMGB1, HSP70 Not tested (210)

aBona fide ICD can be verified only in murine tumor models, as it is determined by vaccination assays in which tumor cells killed by a particular agent in vitro are tested for their ability to invoke protective immunity against subsequent re-challenge with live tumor cells. ICD biomarkers are indicated only if detected in a context appropriate for ICD (i.e., cell surface calreticulin and heat shock proteins, secreted ATP and HMGB1, etc.).